[SGPT determination as a routine screening procedure in blood donors?].
Liver biopsy was carried out in 103 patients with elevated transaminases. In 46 patients (44.5%) histological examination produced the diagnosis of a chronic persistent non-A, non-B hepatitis, whereas in 57 patients (55.5%) steatosis was found. Laboratory findings showed that SGOT is of little use in distinguishing these two diseases. SGPT and the SGOT/SGPT quotient indicate the existence of a CPH-NANB in 93.5 and 89% respectively. We therefore conclude that SGPT should be determined in all blood donors as indirect screening to identify carriers of NANB.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D001706:Biopsy; D001782:Blood Donors; D002353:Carrier State / Q000201:enzymology; D005234:Fatty Liver / Q000473:pathology; D005260:Female; D006526:Hepatitis C / Q000201:enzymology; D006521:Hepatitis, Chronic / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged
D000410:Alanine Transaminase
SGPT-Bestimmung als Routine-Screening bei Blutspendern?